The ubiquitously expressed latent interferon regulatory factor (IRF) 3 transcription factor is activated in response to virus infection by phosphorylation events that target a cluster of Ser/Thr residues, 382 GGASSLEN-TVDLHISNSHPLSLTSDQY 408 
Recognition of invading pathogens such as viruses and bacteria by host cells is known to trigger the activation of multiple latent transcription factors, such as NF-B, AP-1 (ATF-2/cJun), and the interferon regulatory factors (IRFs) 1 (1) (2) (3) . Once activated, these transcription factors regulate the expression of a set of genes encoding for immunomodulatory cytokines and chemokines that are involved in the establishment of the antiviral/bacterial state, which limits the spread of infection through innate and adaptive immune mechanisms (1) (2) (3) . The best characterized component of the innate host defense to virus is the family of transcriptionally activated interferon (IFN) proteins, which include type I IFN-␣ and IFN-␤ and type II IFN-␥. Type I IFNs are mainly induced in response to infection by various types of RNA and DNA viruses (2, 4) , although the bacterial endotoxin lipopolysaccharide (LPS) induces production of IFN in certain cells, albeit at low levels (5, 6) . Once produced, these secreted proteins act in a paracrine fashion to induce gene expression in target cells in the adjacent microenvironment through engagement of cell surface IFN receptors and the JAK-STAT signaling pathway. The ISGF3 complex (ISGF3␥/IRF-9-STAT1-STAT2) binds to interferon-stimulated response elements (ISRE) found in numerous IFN-induced genes, such as 2Ј-5Ј oligoadenylate synthase and the doublestranded (ds) RNA-activated kinase, resulting in the induction of proteins that impair viral gene expression and replication (2, 4) . IRF-3 is part of the IRF family of transcription factors that includes nine members with distinct roles in host defense against pathogens, immunomodulation, and growth control (for review see Refs. 3, 7, and 8) . Previous studies have demonstrated that the C-terminal region of IRF-3, which comprises a cluster of phosphoacceptor sites, 382 GGASSLENTVDLHISN-SHPLSLTSDQY 408 , is phosphorylated as a consequence of virus infection (9, 10) . Radioactive orthophosphate labeling, peptide mapping, phosphoamino acid analysis, and decreased mobility in SDS-PAGE have shown that IRF-3 is a phosphoprotein that is further inducibly phosphorylated upon virus infection (10 -15 (10) are phosphorylated following virus infection and are involved in IRF-3 activation. Indeed, C-terminal phosphorylation is thought to produce a change in protein conformation that reveals the IRF association domain and the DNA-binding domain, thus promoting dimerization and binding to IRF-3 5Ј-GAAA(C/G)(C/ * This work was supported by research grants from the Canadian Institutes of Health Research, the National Cancer Institute of Canada, and the Canadian Network for Vaccines and Immunotherapeutics. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ These authors contributed equally to this work. G)GAAN(T/C)-3Ј consensus DNA-binding site (9, 10, 16) . In addition, IRF-3 C-terminal phosphorylation is required for association with the histone acetyltransferase nuclear proteins CBP and p300 (9, 10, 16) causing IRF-3, which normally shuttles into and out of the nucleus, to become predominantly nuclear (9, 10, 17) . The activated form of IRF-3, bound to CBP, induces transcription through distinct positive regulatory domains (PRD) in the type I IFN promoters and through select ISRE sites found in other genes such as the chemokine RAN-TES, the cytokine interleukin-15, and IFN-stimulated gene (ISG) 56 (10 -12, 15, 18 -22) . Finally, phosphorylation of IRF-3 is thought to induce its degradation by a proteasome-mediated mechanism (10, 23) . In addition to virus infection, other stimuli such as LPS and poly(I-C) have been shown to induce IRF-3 activation (9, 12, 15, 24 -28) . However, no phosphorylation of IRF-3 in response to poly(I-C) treatment has been demonstrated. In this case, IRF-3 activation has been observed through nuclear accumulation, DNA binding activity, coactivator association, and gene induction (9, 12, 15, 24) . On the other hand, phosphorylation of IRF-3 in response to LPS was demonstrated (26) but not sufficiently to detail the precise phosphoacceptor sites.
The in vivo signaling pathways leading to IRF-3 phosphorylation and activation as well as the precise phosphoacceptor sites remain to be elucidated. Previous studies have demonstrated inducible N-terminal phosphorylation of IRF-3 following the activation of mitogen-activated protein kinase kinase kinase pathways (13) . More recently, the activation of DNA-PK following virus infection was shown to induce Thr 135 phosphorylation (29) . However, no convincing physiological roles have been ascribed to these covalent modifications. In the present study, we characterized the minimal phosphoacceptor site(s) involved in the in vivo activation of IRF-3 following treatment with known inducers. Of the seven potential phosphoacceptor sites present in the C-terminal cluster, a single point mutation of Ser 396 to Asp (S396D) was sufficient to generate a strong constitutively active form of IRF-3. Moreover, by using a novel phosphospecific antibody, we show for the first time that Ser 396 is phosphorylated in vivo following virus infection, nucleocapsid (N) expression or dsRNA treatment.
MATERIALS AND METHODS
Reagents-LPS (L-2654) was purchased from Sigma and dissolved in distilled water. Poly(I-C) was purchased from Amersham Biosciences and resuspended in phosphate-buffered saline. Sendai virus (SeV) was a generous gift of Dr. Ilkka Julkunen (Public Health Research Institute, Helsinki, Finland).
Plasmid Constructions and Mutagenesis-wtIRF-3, wtIRF-3 5A, wtIRF-3 5D, wtIRF-3 3D, wtIRF-3 J2A, and wtIRF-3 J2D pFLAG constructs and the luciferase reporter plasmids IFN␣ promoter (IFNA1 pGL-3), IFN␤ promoter (IFNB pGL-3), and the RANTES promoter (RANTES pGL-3) were described previously (13, 18, 21) . The expression constructs encoding different IRF-3 C-terminal point mutants pFLAG-IRF-3 3A, 2D, 2A, S396A, S396D, S398A, S398D, S398A/S402A, and S398D/S402D were generated by overlap PCR mutagenesis using Vent DNA polymerase. The pCMV-2 measles N expression construct has been described previously (30) . SeV N cDNA was subcloned from pGEM SeV N plasmid (a gift from Dr. Illka Julkunen) using 5Ј-AATGGCTG-GGTTGTTGAGCACCTTC-3Ј and 5Ј-TTAGATTCCTCCCATCCCAGCT-GCT-3Ј as forward and reverse primers, respectively. The PCR-generated fragment was subcloned into pCMV-2.
Cell Culture-Human embryonic kidney (HEK) 293 cells were grown in ␣-minimum essential medium. HEC-1B cells and the astrocytoma cell line U373 overexpressing the Toll-like receptor (TLR)-4 coreceptor CD14 (U373/CD14), a gift from Dr. Michael David (University of California, San Diego, CA), were cultured in Dulbecco's modified Eagle's medium. The media were supplemented with 10% fetal bovine serum and antibiotics. U937 cells were grown in RPMI supplemented with 5% fetal clone (Hyclone) and antibiotics.
Transfections, Luciferase Assays, Treatments, and Infection-All of the transfections were carried out on subconfluent HEK 293 cells (calcium phosphate coprecipitation method) or HEC-1B cells (FuGENE method) grown in 60-mm Petri dishes or 24-well plates (for the luciferase assay). 5 g of DNA constructs (per 60-mm dish) or 10 ng of pRLTK reporter (Renilla luciferase for internal control), 100 ng of pGL3 reporter (firefly luciferase, experimental reporter), and 250 ng of pFLAG expression plasmids (24-well plate) were introduced into HEK 293 cells. At 36 h, the cells were collected, washed in ice-cold phosphate-buffered saline, and assayed for reporter gene activities (Promega). Infections with SeV as well as treatments with poly(I-C) and LPS were accomplished in serum-free medium for the first 2 h, after which 10% fetal bovine serum was added for the rest of the incubation period. Whole cell extracts (WCE) were prepared in Nonidet P-40 lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 10% glycerol, 30 mM NaF, 1.0 mM Na 3 VO 4 , 40 mM ␤-glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride, and 5 g/ml of each leupeptin, pepstatin, and aprotinin) and stored at Ϫ80°C.
Reverse Transcriptase-PCR-Total RNA was harvested using Trizol reagent (Invitrogen) as recommended by the manufacturer. RNA was reverse transcribed with Superscript (Invitrogen), and the resulting cDNA were used in a PCR with the primers described for the original cloning of virus N cDNAs (see above) at an annealing temperature of 60°C using Taq DNA polymerase (Amersham Biosciences).
Peptide and Antibody Production-To generate the polyclonal antibody specific for IRF-3 phosphorylated at Ser 396 , termed HIS5033, a phosphopeptide corresponding to residues 388 -402 of human IRF-3, KENTVDLHIS(PO 4 Ϫ )NSHPLS, was synthetized (W. M. Keck Biotechnology Resource Center), coupled to keyhole limpet hemocyanin, and used to immunize rabbits (Pocono Rabbit Farms & Laboratory, Inc, Canadensis, PA). Briefly, 2 mg of peptide in phosphate-buffered saline was coupled to 5 mg of keyhole limpet hemocyanin (Sigma) in 0.2% glutaraldehyde. After neutralization with glycine, the coupled peptide was dialyzed overnight against cold phosphate-buffered saline and resuspended at a concentration of 2 mg/ml for immunization.
Immunoblot Analysis-To analyze the state of IRF-3 phosphorylation and to confirm the expression of the transgenes, WCE (30 -60 g) were subjected to electrophoresis on 7.5% or 10% acrylamide gels. The proteins were electrophoretically transferred to Hybond-C nitrocellulose membranes (Nycomed Amersham, Inc.) in 25 mM Tris, 192 mM glycine, and 20% methanol. The membranes were blocked in Trisbuffered saline containing 5% nonfat dry milk and 0.1% Tween 20 for 1 h at 25°C before incubation for 2 h at 25°C with anti-IRF-3 (Santa Cruz; SC-9082), anti-FLAG M2 (Sigma), anti-IB␣ (MAD 10) (1 g/ml), anti-MYC (9E10) (1 g/ml), or anti-ISG56 (a gift from Dr. G. Sen (Cleveland, OH) (1:1000) in blocking solution. For the phosphospecific antibodies anti-IB␣ Ser 32 phosphospecific antibody (1:2000) (New England Biolab) and HIS5033 (1:10000), the membranes were incubated in blocking solution for 1 h at 25°C followed by incubation in Tris-buffered saline containing 5% bovine serum albumin and 0.1% Tween 20 for overnight at 4°C. After washing four times in Trisbuffered saline, 0.1% Tween 20, the membranes were incubated for 1 h with horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (1:10000) in blocking solution. Immunoreactive bands were visualized by enhanced chemiluminescence (PerkinElmer Life Sciences). For coimmunoprecipitation studies, WCE (500 g) were incubated with 1 g of anti-CBP antibody A-22 (Santa Cruz) or 1 g of anti-FLAG antibody M2 linked to 30 l of protein A-or protein G-Sepharose beads, respectively, for 3 h at 4°C (Amersham Biosciences). The beads were washed five times with Nonidet P-40 lysis buffer and resuspended in denaturating sample buffer, and the eluted IRF-3 proteins associated with CBP were analyzed by immunoblotting.
RESULTS

IRF-3 S396D Phosphomimetic Is a Strong Transactivator of PRD I-III-and ISRE-containing Promoters-
To delineate the minimal residues required for IRF-3 activation, the effects of various phosphomimetic point mutations (Fig. 1A) on the transactivating potential of IRF-3 were analyzed using reporter gene assays with the IRF-3-responsive promoters IFN␣1, IFN␤, and RANTES (Fig. 1B) . Overexpression of wtIRF-3 alone minimally induced IFN␣1, IFN␤, and RANTES promoter activities, as demonstrated previously (10, 21, 31) , whereas introduction of the C-terminal point mutation, S396D, enhanced IRF-3 transactivating potential over wtIRF-3 by 13-, 14-, and 11-fold for the IFN␣1, IFN␤, and RANTES promoters, respectively (Fig. 1B) . The IFN␣1, IFN␤, and RANTES promot-
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ers were also activated by the double point mutant 2D (13-, 12-, and 12-fold over wtIRF-3, respectively) and, as previously reported (10, 16, 18, 21) , the multiple point mutant 5D (9-, 5.5-, and 8-fold induction, respectively). However, the point mutants S398D, S398D/S402D, and S402D/S404D/S405D exhibited only intermediate effects, and the S385D/S386D mutant did not induce these promoters. Our initial result thus demonstrates that substitution of Ser 396 with the phosphomimetic Asp is sufficient to generate a constitutively active form of IRF-3 that functions as a strong activator of promoters containing PRD I-III or ISRE regulatory elements.
The Minimal Phosphoacceptor Site Required for IRF-3 Association with CBP Coactivator Maps to Ser
396 -Formation of the IRF-3 holocomplex, which consists of an IRF-3 dimer and CBP or p300 coactivators, is a critical step in the activation of the transcription factor (32) . Association with CBP/p300 is strictly localized to the nucleus and tethers IRF-3 in the nucleus after induction with viruses (16, 17, 32) . Therefore, the relationship between the different IRF-3 point mutants and CBP association was evaluated using coimmunoprecipitation assays. As shown in Fig. 2 , infection with SeV stimulated wtIRF-3 and CBP association (Fig. 2, A and B, lanes 1 and 2) . Mutation of Ser 396 to Ala completely abrogated virus-induced CBP association ( Fig. 2A, lanes 3 and 4) , whereas the phosphomimetic point mutant S396D constitutively associated with CBP (Fig.  2B, compare lanes 1 and 3) , an association that was enhanced following virus infection (Fig. 2B, lane 4) . Similar results were obtained with the other mutants IRF-3 2A (Fig. 2A, lanes 7 and  8) and IRF-3 5A (Fig. 2A, lanes 13 and 14) , where no inducible association with CBP was observed. Conversely, strong constitutive binding to CBP was present with IRF-3 2D (Fig. 2B, lane  7) and IRF-3 5D (Fig. 2B, lane 13) . As a control for these results, the S398A form of IRF-3 was still able to associate with CBP following virus infection ( Fig. 2A, lanes 5 and 6) , but only a basal association of the phosphomimetic counterpart IRF-3 S398D with CBP was observed in the absence of infection (Fig.  2B, compare lanes 1 and 5) . As previously reported (16), coactivator association was not observed with either the IRF-3 J2A or J2D mutants (Fig. 2, A and B, lanes 15 and 16) . As discussed previously (30) , Ser 385/386 phosphorylation may be required for the sequential phosphorylation of the Ser/Thr cluster at amino acids 396 -405. Together these data indicate that Ser 396 is a critical phosphoacceptor site for coactivator CBP/p300 association and that a clear correlation exists between the capacity of the point mutants to induce promoter activity and to associate with the CBP coactivator. 6 cells) for 12 h. WCE (500 g) were immunoprecipitated (IP) with anti-CBP antibody A22 absorbed to protein A-Sepharose beads. The immunoprecipitated proteins were resolved by SDS gel electrophoresis on 7.5% acrylamide gel and transferred to nitrocellulose membrane. The membranes were probed with anti-FLAG antibody. WCE (25 g; 5% input) run on a 7.5% acrylamide gel, transferred to membrane, and immunoblotted with anti-FLAG antibody are also shown for both set of mutants: alanine (A) and aspartic acid substitutions (B).
IRF-3 S396D Expression Induces the Endogenous
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tandem ISRE sites, mutation of which results in the complete loss of promoter activation by IRF-3 5D (20) . To determine the effect of transient expression of the different phosphomimetic IRF-3 forms on the induction of the endogenous ISG56 in the IFN-unresponsive HEC-1B cells, induction of ISG56 was analyzed by immunoblot (Fig. 3) . Sendai virus infection resulted in 25-fold induction of ISG56 (Fig. 3, lane 10) , whereas wtIRF-3 expression alone resulted in a weak induction of ISG56 protein of 2.6-fold (Fig. 3, lane 2) . Transfection of S396D as well as 2D and 5D resulted in a stronger induction of the protein of 5.2-, 6.4-, and 10-fold, respectively (Fig. 3, lanes 3, 5, and 8) . However, only weak inductions between 2.2-and 3.5-fold were observed with the other point mutants (Fig. 3, lanes 4, 6, 7, and  9) . Thus, mutation at position 396 is sufficient to create a phosphomimetic form of IRF-3 that allows stable binding to CBP/p300 coactivator, transactivation of reporter genes controlled by PRD and ISRE response elements, and, importantly, enhancement of endogenous expression of ISG56.
In Vivo Phosphorylation of Ser 396 of IRF-3 following Virus Infection-To verify whether in vivo phosphorylation of IRF-3 occurred at Ser
396 , an antibody directed against a phosphopeptide spanning Ser 396 , named HIS5033, was raised (see "Materials and Methods"). Fig. 4A shows that the antibody reacted only toward the transfected FLAG-wtIRF-3 transgene when cells were infected with SeV; indeed, no signal was observed in IRF-3 S396A-overexpressing cells infected with SeV. In contrast, Fig. 4B shows a specific endogenous signal when extracts derived from SeV-infected HEK 293 cells were analyzed by immunoblot using the phosphospecific 396-P antibody HIS5033 (Fig. 4B, lanes 2 and 3) . Reblotting of the stripped membrane with an anti-IRF-3 antibody (SC-9082) showed that the specific signal observed with HIS5033 antibody corresponded to the slowly migrating form of IRF-3, previously shown to represent the activated form of IRF-3 (Fig. 4B, compare lanes 4 -6) (10, 13) . Although IRF-3 degradation had already reduced the amount of IRF-3 in these cells at 6 h postinfection (Fig. 4B, lane 5) and the IRF-3 signal was difficult to detect with anti-IRF-3 antibody (SC-9082), the phosphospecific antibody HIS5033 reacted strongly under these conditions (Fig.  4B, compare lanes 2 and 5 and lanes 3 and 6) .
To investigate whether the phosphorylation of Ser 396 could be mimicked by expression of viral N protein (30) , transfection experiments were performed with constructs expressing measles virus and SeV N for 36 h post-transfection. As shown in Fig. 4C , expression of either SeV or measles virus N induced higher migrating forms of IRF-3 (middle panel). Use of HIS5033 antibody revealed that Ser 396 was phosphorylated under these conditions (Fig. 4C, top panel) . Taken together, these results demonstrate that virus infection or expression of viral nucleocapsid protein is sufficient to induce Ser (lanes 1-3) . The membranes were stripped and reprobed with the anti-IRF-3 antibody SC-9082 (lanes 4 -6) . C, HEK 293 cells were transiently transfected with expression plasmids encoding either SeV or measles virus N. At 36 h post-transfection WCE (50 g) were analyzed as detailed above using IRF-3 396 phosphospecific HIS5033 (upper panel) and anti-IRF-3 antibody SC-9082 (middle panel). Expression of SeV and measles virus N was analyzed by reverse transcriptase-PCR using the full-length primers described under "Materials and Methods."
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was analyzed by immunoblot using the phosphospecific antibody HIS5033. As shown in Fig. 5 (A and B) , both SeV and poly(I-C) induced Ser 396 phosphorylation of IRF-3 with maximum signals detected at 4 and 2 h, respectively (Fig. 5, A, lanes  4 -7, and B, lanes 3 and 4) . Specific phosphoserine 396 signal was detected when IRF-3 first displayed a retarded mobility in SDS-PAGE, as observed by the use of the SC-9082 antibody (Fig. 5, A, lanes 12-15, and B, lanes 11-13) . However, no signal was detected when cells were treated with LPS (Fig. 5C, lanes  1-8) . Furthermore, qualitative and temporal differences in the kinetics of IRF-3 Ser 396 phosphorylation by SeV and poly(I-C) were identified: 1) Although phosphorylation of IRF-3 in response to SeV infection, first detected at 4 h post-infection, was followed by degradation (Fig. 5A, lanes 12-16) , phosphorylation in response to poly(I-C) was detected at 2 h and did not lead to degradation. Rather, IRF-3 appeared to be dephosphorylated over time and returned to basal forms (Fig. 5B, lanes 12-16) . 2) Although Ser 396 phosphorylation was not detected after LPS stimulation, a transient shift from form I to form II (Fig. 5C,  lanes 13-15) was observed. This transition was previously shown to correlate with an N-terminal phosphorylation possibly mediated through a mitogen-activated protein kinase kinase kinase-related pathway (13) . To verify that LPS treatment was efficient, phosphorylation of Ser 32 of IB␣ by the IB kinase complex was measured using either the Ser 32 phosphospecific antibody (Fig. 5F, lanes 2-8) or change of mobility in SDS gel observed by the use of the IB␣-specific MAD 10 antibody (Fig. 5F, lanes 11-16) . Together, these data demonstrate that Ser 396 phosphorylation of IRF-3 occurs in vivo following treatment with inducers such as SeV and poly(I-C), but not LPS.
IRF-3 Ser 396 Phosphorylation Is Not Detected in LPStreated U937 Cells-To further analyze the LPS effect, IRF-3 Ser
396 phosphorylation was also examined in the monocytic cell line U937. Fig. 6A demonstrates that infection of U937 cells with SeV resulted in IRF-3 Ser 396 phosphorylation beginning as early as 2 h post-infection, whereas no signal with HIS5033 antibody was detected with cell extracts derived from LPS-stimulated cells (Fig. 6B) . Both SeV and LPS were able to induce the phosphorylation of IB␣ (Fig. 6, C and D) .
DISCUSSION
The rate-limiting step in the activation of IRF-3 is its phosphorylation by at least one unidentified kinase, namely virusactivated kinase, activated following virus infection or dsRNA treatment (9, 10, (12) (13) (14) (15) 24) . The major phosphoacceptor sites described to date are clustered in the C-terminal end of the protein. Yoneyama et al. (9) (10) . Mutation of these sites to aspartic acid generates a strong constitutive active form of IRF-3, IRF-3 5D, in which slow migration in SDS-PAGE, dimerization, CBP association, DNA binding, and gene transactivation occur without the need of virus infection. Conversely, generation of an IRF-3 mutant in which the five phosphoacceptor sites are replaced with alanine completely inhibits virus-induced dimerization, coactivator association, and transactivation activity (10, 13, 16, 18, 21) .
Despite these molecular observations, the contribution of different phosphorylation sites has not been addressed in vivo. In a previous study (21) , we showed that the IRF-3 2A mutant behaves like the IRF-3 5A mutant. In fact, the IRF-3 2A mutant is not phosphorylated in response to virus infection. Moreover, as determined through immunofluorescence analysis, the IRF-3 2A-GFP protein does not translocate to the nucleus. These results point out the importance of these two residues in the IRF-3 activation process. In the present study, we demonstrate that mutation of Ser 396 to Asp is the minimal mutation required to produce a strong phosphomimetic form of IRF-3. This observation was confirmed using a phosphospecific anti- 
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body raised against a peptide containing the phosphorylated Ser residue at position 396. We show for the first time that this site is phosphorylated in vivo when cells are exposed to SeV, nucleocapsid, or poly(I-C), well characterized inducers of IRF-3. Together these results demonstrate that the Ser 396 residue is critical for IRF-3 activation.
Recent studies also suggested LPS as another IRF-3 inducer (25) (26) (27) (28) . Indeed, treatment of murine macrophages with LPS was shown to induce the production of IFN, suggesting the activation of some IRF members (5, 6) . In this context, Navarro and David (25) reported that LPS treatment of human U373 astrocytoma cells resulted in IRF-3 activation (nuclear translocation and DNA binding activity) via a TLRand p38-dependent pathway. This observation was supported by recent findings demonstrating that IRF-3 mediates a TLR-3/TLR-4-specific antiviral gene program when murine B cells are exposed to dsRNA and LPS, respectively (35) . In addition, it has recently been shown through gene disruption targeting studies that neither the universal adaptor protein MyD88 nor the novel adaptor TIRAP/Mal (36) were involved in IRF-3 activation following LPS stimulation of peritoneal macrophages (26, 37) . The adaptor protein involved in LPS-induced IRF-3 activation has yet to be identified. However, the newly identified adaptor protein TRIF appears to be involved in dsRNA-induced IRF-3 activation by TLR-3 (Ref. 38 and references therein), which might also be the case for IRF-3 activation by TLR-4. Our data suggest that LPS-induced activation of IRF-3 does not lead to phosphorylation of Ser 396 . How LPS activates IRF-3 remains to be determined; treatment of target cells with LPS generates multiple signaling pathways in addition to IKK/JNK/p38, such as protein kinase C, Src-type tyrosine kinases, and the phosphatidylinositol 3-kinase-protein kinase B pathway (1) . Phosphorylation of IRF-3 in response to LPS was shown by slower mobility in one-dimensional immunoblot (26) . However, the analysis of IRF-3 phosphorylation was not resolved sufficiently to delineate the different IRF-3 phosphorylated forms. As described previously, stress inducers induce N-terminal IRF-3 phosphorylation, which is characterized by a shift from form I to form II in immunoblot analysis (13) , an effect also observed with LPS in the U373 astrocytoma cell line (Fig. 5C, lanes 13  and 14) and B16 melanoma cells.
2 Therefore, N-terminal phosphorylation or C-terminal phosphorylation at other Ser or Thr residues may be induced by LPS and therefore involve other signaling pathways in the activation of IRF-3. However, a limited sensitivity of the phosphospecific antibody cannot be ruled out, and a weak but significant phosphorylation of IRF-3 at Ser 396 might occur following TLR-4 activation.
Based on the capacity of bacterially produced IRF-3 to bind the ISRE in vitro (22, 39) , it was concluded that mutation of Ser 396 to Asp in recombinant IRF-3 eliminated DNA binding (39) . This observation is in apparent contradiction with the results of the present study demonstrating that ectopically expressed IRF-3 S396D acts as a strong transactivator of ISRE containing promoters (Figs. 1 and 3) . However, a recent study demonstrated that CBP/p300 was required for the DNA binding activity of the holocomplex (32) . This observation may explain why no stable binding to DNA was observed with recombinant IRF-3 S396D in the absence of coactivators (39) and strengthens the observation that IRF-3 S396D is a strong IRF-3 phosphomimetic in part because of its capacity to bind CBP (Fig. 2) .
Another surprising finding was the relative stability of the phosphomimetic point mutants (data not shown). Indeed, whereas inactive IRF-3 is very stable (40) , virus infection results in a rapid degradation of IRF-3 via a proteasome-dependent pathway (10, 13, 23) . Based on the observation that virusinduced degradation of IRF-3 always follows phosphorylation (10, 13), we assumed that the destabilization of IRF-3 might be the consequence of phosphorylation of residues in the C-terminal cluster. Based on two observations, this is unlikely to be the signal for degradation of IRF-3 in vivo: 1) introduction of phosphomimetic point mutations did not lead to increased degradation of IRF-3 when the mutants were overexpressed in HEK 293 cells (data not shown) and 2) treatment of U373/CD14 with poly(I-C) clearly induced IRF-3 Ser 396 phosphorylation (Fig.  5B, lane 4) . However, this phosphorylation, which induces a shift in the migration profile of IRF-3, was not followed by degradation (Fig. 5B, lanes 11-16) . IRF-3 instability may therefore be specific to a product of the virus life cycle that recognizes activated IRF-3 and targets it for degradation by the proteasome pathway. Finally, the critical role of Ser 396 phosphorylation in IRF-3 activation following virus infection and the development of a specific and sensitive phosphospecific antibody against Ser 396 may be useful as a research and diagnostic tool as a marker of virus infection.
